Development of proteasome inhibitors as research tools and cancer drugs
MetadataShow full item record
CitationGoldberg, Alfred L. 2012. Development of proteasome inhibitors as research tools and cancer drugs. The Journal of Cell Biology 199(4): 583-588.
AbstractThe proteasome is the primary site for protein degradation in mammalian cells, and proteasome inhibitors have been invaluable tools in clarifying its cellular functions. The anticancer agent bortezomib inhibits the major peptidase sites in the proteasome’s 20S core particle. It is a “blockbuster drug” that has led to dramatic improvements in the treatment of multiple myeloma, a cancer of plasma cells. The development of proteasome inhibitors illustrates the unpredictability, frustrations, and potential rewards of drug development but also emphasizes the dependence of medical advances on basic biological research.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11179739
- HMS Scholarly Articles